119 related articles for article (PubMed ID: 3712213)
21. Disposition of hexobarbital in the rat. Estimation of "first-pass" elimination and influence of ether anesthesia.
Vermeulen NP; Danhof M; Setiawan I; Breimer DD
J Pharmacol Exp Ther; 1983 Jul; 226(1):201-5. PubMed ID: 6864540
[TBL] [Abstract][Full Text] [Related]
22. Influence of the rate of hepatic portal vein infusion on hexobarbital pharmacokinetics in the rat.
Joeres RP; Vermeulen NP; Breimer DD
Pharmacology; 1988; 36(3):210-6. PubMed ID: 3368506
[TBL] [Abstract][Full Text] [Related]
23. The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine.
Bleske BE; Carver PL; Annesley TM; Bleske JR; Morady F
J Clin Pharmacol; 1990 Oct; 30(10):911-5. PubMed ID: 2229451
[TBL] [Abstract][Full Text] [Related]
24. Elimination kinetic of high polar metabolites pool of quinidine from human serum.
Camsonne R; Moulin MA; Charbonneau P; Bazin C
Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396
[TBL] [Abstract][Full Text] [Related]
25. Criticism of pharmacokinetic clearance concepts.
Keller F; Schoole J
Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
[TBL] [Abstract][Full Text] [Related]
26. Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats.
Fremstad D; Jacobsen S; Lunde KM
Acta Pharmacol Toxicol (Copenh); 1977 Aug; 41(2):161-76. PubMed ID: 579055
[TBL] [Abstract][Full Text] [Related]
27. Hepatic drug clearance following traumatic injury.
Slaughter RL; Hassett JM
Drug Intell Clin Pharm; 1985 Nov; 19(11):799-806. PubMed ID: 3905320
[TBL] [Abstract][Full Text] [Related]
28. Comparison of disposition parameters of quinidine and quinine in the rat.
Watari N; Wakamatsu A; Kaneniwa N
J Pharmacobiodyn; 1989 Oct; 12(10):608-15. PubMed ID: 2630631
[TBL] [Abstract][Full Text] [Related]
29. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
[TBL] [Abstract][Full Text] [Related]
30. Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations.
Blanchard N; Hewitt NJ; Silber P; Jones H; Coassolo P; Lavé T
J Pharm Pharmacol; 2006 May; 58(5):633-41. PubMed ID: 16640832
[TBL] [Abstract][Full Text] [Related]
31. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test.
Neuvonen PJ; Tokola RA; Kaste M
Eur J Clin Pharmacol; 1981; 21(3):215-20. PubMed ID: 7318881
[TBL] [Abstract][Full Text] [Related]
32. Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Nakayama K; Kamimura H; Suemizu H; Yoneda N; Nishiwaki M; Iwamoto K; Mizunaga M; Negoro T; Ito S; Yamazaki H; Nomura Y
Drug Metab Pharmacokinet; 2020 Aug; 35(4):389-396. PubMed ID: 32690433
[TBL] [Abstract][Full Text] [Related]
33. Use of tissue disposition data from rats and dogs to determine species differences in input parameters for a physiological model for perchloroethylene.
Dallas CE; Chen XM; Muralidhara S; Varkonyi P; Tackett RL; Bruckner JV
Environ Res; 1994 Oct; 67(1):54-67. PubMed ID: 7925194
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of quinidine related to plasma protein binding in man.
Fremstad D; Nilsen OG; Storstein L; Amlie J; Jacobsen S
Eur J Clin Pharmacol; 1979 Apr; 15(3):187-92. PubMed ID: 456401
[TBL] [Abstract][Full Text] [Related]
35. Digoxin-quinidine interaction in patients with chronic renal failure.
Fenster PE; Hager WD; Perrier D; Powell JR; Graves PE; Michael UF
Circulation; 1982 Dec; 66(6):1277-80. PubMed ID: 7139903
[TBL] [Abstract][Full Text] [Related]
36. Quinidine does not alter antipyrine metabolism.
Bowles SK; Cardozo L; Edwards DJ
J Clin Pharmacol; 1990 Mar; 30(3):267-71. PubMed ID: 2312782
[TBL] [Abstract][Full Text] [Related]
37. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
[TBL] [Abstract][Full Text] [Related]
38. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
Branch RA; Shand DG; Wilkinson GR; Nies AS
J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
[TBL] [Abstract][Full Text] [Related]
39. Digoxin quinidine interaction: a pharmacokinetic study in the isolated perfused rat liver.
Ben-Itzhak J; Bassan HM; Shor R; Lanir A
Life Sci; 1985 Aug; 37(5):411-5. PubMed ID: 4021722
[TBL] [Abstract][Full Text] [Related]
40. Antipyrine pharmacokinetics in the pregnant rat.
Dean M; O'Donnell L; Penglis S; Stock B
Drug Metab Dispos; 1980; 8(4):265-7. PubMed ID: 6105062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
